BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)

-1.72%

Roivant Sciences Ltd.

ROIV

28.06

-1.72%

Feb 6 (Reuters) - Priovant:

PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)
PRIOVANT - BREPOCITINIB WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS
PRIOVANT: PLANS TO PROGRESS CS TO A PIVOTAL PROGRAM WITH A PHASE 3 STUDY STARTING IN CALENDAR YEAR 2026 FOLLOWING ENGAGEMENT WITH FDA

Source text: ID:nGNX6Tw17l

Further company coverage: ROIV.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.